tradingkey.logo
Search
Markets
News
Analysis
Tools
Stock Screener
Learn
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

AbbVie Inc

ABBV
Add to Watchlist
234.760USD
+4.750+2.07%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
414.77BMarket Cap
115.55P/E TTM

AbbVie Inc

234.760
+4.750+2.07%
Overview
Financials
Discussions
Analysis
Company
ProfileRevenueShareholdersCorporate

Overview

Financials

Discussions

Analysis

Company

ProfileRevenueShareholdersCorporate

More Details of AbbVie Inc Company

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

AbbVie Inc Info

Ticker SymbolABBV
Company nameAbbVie Inc
IPO dateJan 02, 2013
CEOMichael (Robert A)
Number of employees55000
Security typeOrdinary Share
Fiscal year-endJan 02
Address1 N Waukegan Rd
CityNORTH CHICAGO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code60064
Phone18479327900
Websitehttps://www.abbvie.com/
Ticker SymbolABBV
IPO dateJan 02, 2013
CEOMichael (Robert A)

Company Executives of AbbVie Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
30.08K
+3.72%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
17.62K
+6.35%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Mr. Thomas J. (Tom) Falk
Mr. Thomas J. (Tom) Falk
Independent Director
Independent Director
5.32K
+21.01%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
39.58K
+2.82%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--

FAQs

Who are the top five shareholders of AbbVie Inc?

The top five shareholders of AbbVie Inc are: Dr. Azita Saleki-Gerhardt, Ph.D.

How many institutions hold shares of AbbVie Inc (ABBV)?

As of 2026Q1, 5703 institutions hold shares of AbbVie Inc, with a combined market value of approximately 1.36B, accounting for 77.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 26641628.00.

What is the biggest source of revenue for AbbVie Inc?

In 2026Q1, the Immunology-SKYRIZI business generated the highest revenue for AbbVie Inc, amounting to 17.56B and accounting for 28.71% of total revenue.
KeyAI